Ann Rheum Dis

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 17 August 2007. doi:10.1136/ard.2007.077263
Annals of the Rheumatic Diseases 2008;67:602-608
Copyright © 2008 BMJ Publishing Group Ltd & European League Against Rheumatism

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow web only appendix
Right arrow All Versions of this Article:
ard.2007.077263v1
ard.2007.077263v2
67/5/602    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Polzer, K
Right arrow Articles by Zwerina, J
PubMed
Right arrow PubMed Citation
Right arrow Articles by Polzer, K
Right arrow Articles by Zwerina, J

EXTENDED REPORTS

Selective p38MAPK isoform expression and activation in antineutrophil cytoplasmatic antibody-associated crescentic glomerulonephritis: role of p38MAPK{alpha}

K Polzer 1, A Soleiman 2, W Baum 1, R Axmann 1, J Distler 1, K Redlich 3, A Kilian 1, G Krönke 1, G Schett 1,3, J Zwerina 1,3

1 Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen, Germany
2 Department of Clinical Pathology, Medical University of Vienna, Austria
3 Department of Internal Medicine 3, Medical University of Vienna, Austria

Correspondence to:
Jochen Zwerina, MD, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Krankenhausstrasse 12, 91054 Erlangen, Germany; jochen.zwerina{at}uk-erlangen.de

Objective: Crescentic glomerulonephritis (crGN) is a frequent and life-threatening manifestation of antineutrophil cytoplasmatic antibody-associated vasculitis. Up-regulation of proinflammatory cytokines contributes to renal damage by activation of p38 mitogen-activated protein kinases (MAPKs). However, it is unclear which of the four p38MAPK isoforms are expressed, activated and hence of major importance in crGN.

Methods: Kidney biopsies of patients with antineutrophil cytoplasmatic antibody-positive crGN and control samples were investigated for the expression and phosphorylation of p38MAPK isoforms and downstream target kinase MAPKAP2 by immunohistochemistry. Expression and functional activation of p38MAPK isoforms by TNF was also assessed in a human podocyte cell line by reverse transcription–polymerase chain reaction, immunoblotting and kinase array.

Results: Strong expression of p38MAPK{alpha}, β and {gamma} isoforms was found in glomerular podocytes and crescents. Infiltrating leucocytes showed predominant p38MAPK{alpha} expression. Activation of p38MAPK and its downstream mediator MAPKAP2 was found in crGN confined to glomerular podocytes, crescents and inflammatory infiltrates. Interestingly, corticosteroid treatment before kidney biopsy diminished p38MAPK activation in crGN. Activated p38MAPK co-localised with {alpha}, β and {gamma} isoforms in podocytes and crescents, while leucocytes showed mainly p38MAPK{alpha} activation. In a human podocyte cell line mRNA and protein of all four p38MAPK isoforms was expressed but only p38MAPK{alpha} was activated upon challenge with TNF.

Conclusions: This study shows selective p38MAPK isoform expression and activation in crGN. Podocytes and podocyte-induce crescent formation is the main source of p38MAPK activation in crGN. TNF is a potent and selective activator of the {alpha}-isoform in podocytes, which therefore appears as a main contributor to proinflammatory signalling in the glomerulum of crGN.








HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 BMJ Publishing Group Ltd & European League Against Rheumatism